FDA approves Eli Lilly’s Trulicity for type 2 diabetic patients

USFDA approves Eli Lilly's Trulicity to reduce cardiovascular risks in type 2 diabetic patients

484
Approved approval nod
Picture: Pixabay
< 1 min. read

USFDA approves Eli Lilly’s Trulicity to reduce cardiovascular risks in type 2 diabetic patients

(Reuters) Eli Lilly and Co said on the U.S. Food and Drug Administration (USFDA) has approved Trulicity for reducing cardiovascular risk factors in type 2 diabetic patients.

The approval makes Trulicity the first and only type 2 diabetes drug approved to reduce heart related risks in adults with and without established cardiovascular disease, the company said in a statement.

Also read: Zydus gets USFDA approval for generic Canasa

LEAVE A REPLY

Please enter your comment!
Please enter your name here